Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Belapectin
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Galectin Reports Positive Outcome from Fifth Monitoring Board Meeting in NAVIGATE Study
Details : GR-MD-02 (belapectin) is a complex carbohydrate drug that targets galectin-3, which is being evaluated with the patients for the treatment of Cirrhotic Portal Hypertension.
Brand Name : GR-MD-02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 09, 2024
Lead Product(s) : Belapectin
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GR-MD-02 (belapectin) is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis. Belapectin binds to galectin-3 and disrupts its major role in diseases that involve scarring of organs, including f...
Brand Name : GR-MD-02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 03, 2023
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GR-MD-02 (belapectin) is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis. Belapectin binds to galectin-3 and disrupts its major role in diseases that involve scarring of organs, including f...
Brand Name : GR-MD-02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 16, 2023
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GR-MD-02 (belapectin) is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis.Belapectin binds to galectin-3 and disrupts its role in diseases that involve scarring of organs.
Brand Name : GR-MD-02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 02, 2023
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GR-MD-02 (Belapectin) is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis. Belapectin binds to galectin-3 and disrupts its major role in diseases that involve scarring of organs, including f...
Brand Name : GR-MD-02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 05, 2023
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GR-MD-02 (belapectin) is complex carbohydrate drug that targets galectin-3, a critical protein in pathogenesis of NASH and fibrosis also it binds to galectin-3 and disrupts its function.
Brand Name : GR-MD-02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 01, 2022
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Galectin Therapeutics to Present in Upcoming Conferences
Details : Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis. Belapectin binds to galectin-3 and disrupts its function.
Brand Name : GR-MD-02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 14, 2022
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Belapectin,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis. Preclinical data in animals have shown that belapectin has robust treatment effects in reversing liver fibrosis and cirrhosis.
Brand Name : GR-MD-02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 12, 2022
Lead Product(s) : Belapectin,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis. Preclinical data in animals have shown that belapectin has robust treatment effects in reversing liver fibrosis and cirrhosis.
Brand Name : GR-MD-02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 14, 2022
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Galectin-3, a glycan binding protein, plays a central role to foster liver inflammation and fibrosis in NASH cirrhosis. Belapectin is a galectin-3 inhibitor in development for NASH cirrhosis.
Brand Name : GR-MD-02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 05, 2021
Lead Product(s) : Belapectin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?